Clinical advances in Blinatumomab for pediatric acute lymphoblastic leukemia
10.3760/cma.j.cn101070-20240902-00558
- VernacularTitle:贝林妥欧单抗治疗儿童急性淋巴细胞白血病的临床研究进展
- Author:
Wei WANG
1
;
Xiaopeng MA
1
;
Yongjun FANG
1
Author Information
1. 南京医科大学附属儿童医院血液肿瘤科，南京 210008
- Publication Type:Journal Article
- Keywords:
Acute lymphoblastic leukemia;
Bispecific T-cell engager;
Blinatumomab;
Child
- From:
Chinese Journal of Applied Clinical Pediatrics
2025;40(9):704-709
- CountryChina
- Language:Chinese
-
Abstract:
Blinatumomab, a bispecific T-cell engager targeting CD3 and CD19 simultaneously, recruits endogenous T lymphocytes to induce tumor cell apoptosis via cytolytic synapse formation and inflammatory cytokine release.Approved by the U. S.Food and Drug Administration and China′s National Medical Products Administration for relapsed/refractory (R/R) precursor B-cell acute lymphoblastic leukemia (ALL) in adults and children, its clinical applications are expanding into earlier treatment phases.This review synthesizes the therapeutic mechanisms and evolving clinical applications of Blinatumomab in pediatric R/R ALL.
